Hyderabad, Jul 27 (PTI): Avra Laboratories Pvt Ltd,a city based pharma company, has been granted regulatory approval by the Central Drugs Standard Control Organisation (CDSCO) to manufacture and marketFavipiravir API, which will help patients suffering from COVID-19.

The company, in a press release, said it has developed an alternative low cost and highly efficient manufacturing process and is now supplying commercial quantities to drug maker Cipla for the launch of Ciplenza, the generic version of Favipiravir.

Also Read | Realme V5 Smartphone to Be Launched on August 3; Check Expected Prices, Features, Variants & Specifications.

A V Rama Rao, Chairman, Avra Laboratoriessaid, "I am very pleased to be working with Cipla and Dr Yusuf Hamied again, with whom I share a five-decade long association and friendship, during which time we collaborated on several projects to produce lifesaving drugs, including anti-cancer, anti-HIV/AIDS and several other generic products.

The current pandemic has brought us together to work tirelessly for the speedy launch of Favipiravir", Rama Rao, a former director of CSIR-IICT foundedAvra Laboratories, said.

Also Read | 'Rozgar Bazar' Job Portal Launched by Delhi Government: Here's How to Register, Sign Up and Apply for Jobs Online at jobs.delhi.gov.in.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)